Key result
Low-dose quinidine suppresses recurrent VT/VF in ~90% of Brugada syndrome patients.
Why the study?
Does low-dose quinidine prevent recurrence of ventricular arrhythmias in Brugada syndrome patients with recurrent ICD shocks?
Observational (n=10)
No
Does low-dose quinidine prevent recurrence of ventricular arrhythmias in Brugada syndrome patients with recurrent ICD shocks?
Low-dose quinidine (≤200 mg/day) may be an effective and well-tolerated adjunctive therapy for preventing recurrent VT/VF in Brugada syndrome patients experiencing frequent ICD shocks.
May support low-dose quinidine for recurrent shocks in Brugada syndrome; leaves open confirmation in randomized trials.
BACKGROUND: Only implantable cardioverter defibrillators (ICD) have been proven to prevent sudden cardiac death (SCD) in patients with Brugada syndrome (BrS). However, ICD discharge, whether appropriate or inappropriate, leads to impaired quality of life and even increases rehospitalization. Quinidine might prevent the recurrence of ventricular arrhythmia (VA); however, the effect of low-dose quinidine for preventing spontaneous arrhythmias remains less clear. METHODS: In our cardiology center, 10 confirmed patients with BrS (all men, mean age 38.7 ± 6.72 years) who underwent appropriate ICD shocks due to recurrent VAs were treated with quinidine (≤200 mg/day) and followed regularly. RESULTS: All the patients underwent ICD shocks due to ventricular tachycardia (VT)/ventricular fibrillation (VF) before taking quinidine. A 24-hour distribution of VT/VF demonstrated that most of the events occurred in the sleeping time from 22:00 to 8:00. Quinidine prevented recurrence of VAs in nine patients. The other one patient took quinidine discontinuously because of anxiety suffered from less episodes of VA, and after psychological guidance, he took quinidine 200 mg/day and experienced no VA episodes from then on. In our series, only one patient suffered leukopenia related to quinidine. No other side effect was observed. CONCLUSIONS: Quinidine with a very low dose (≤200 mg/day) well controlled VT/VF recurrence for a long-term period in Chinese patients with BrS. Administration (at 21:00) according to the circadian distribution of VT/VF episodes might increase the efficiency and improve the patient's tolerance.
No takes yet. Share an insight, caveat, or question.
Shen et al. (2016) conducted an observational in Brugada syndrome (n=10). Quinidine vs. No quinidine (before treatment) was evaluated on Recurrence of ventricular tachycardia (VT) or ventricular fibrillation (VF) episodes. Low-dose quinidine (≤200 mg/day) effectively controlled VT/VF recurrence for a long-term period in 9 out of 10 Chinese Brugada syndrome patients with recurrent ICD shocks.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: